PTEN基因对肺癌作用及治疗的应用研究进展  

Research progress on the effect and therapeutic application of PTEN in lung cancer

作　　者：萧阳 毕虹 金志贤[1] 杜俊毅[1] 黄照明[1] 陈敏[1] XIAO Yang;BI Hong;JIN Zhixian;DU Junyi;HUANG Zhaoming;CHEN Min(Department of Respiratory and Critical Care Medicine,Ganmei Hospital Affiliated to Kunming Medical University,Yunnan Province,Kunming650000,China)

机构地区：[1]昆明医科大学附属甘美医院呼吸与危重症医学科,云南昆明650000

出　　处：《中国医药导报》2023年第31期72-75,共4页China Medical Herald

基　　金：云南省科技厅科技应用基础研究计划项目(昆医联合专项-面上项目)(202101AY070001-213)。

摘　　要：PTEN基因是肺癌重要的抑癌基因,通过抑制PIP3生成,从而抑制AKT、mTOR活化,一方面直接抑制肿瘤细胞,另一方面减弱肿瘤间质对肿瘤细胞支持作用,抑制肺癌的发生、生长和转移。PTEN基因表达下降引起肺癌治疗耐药的发生,并反映患者的预后。然而因表观遗传和翻译后调控的存在,PTEN蛋白缺失明显高于PTEN基因突变发生率,因此相比于靶向PTEN基因的治疗药物,通过提高恶性肿瘤的PTEN蛋白表达可能是针对PTEN基因治疗肺癌及抑制耐药的一种更有前景的方法。PTEN is an important tumor suppressor gene of lung cancer,which inhibits the activation of AKT and mTOR by inhibiting PIP3 production.On the one hand,it directly inhibits tumor cells.On the other hand,it weakens the supporting effect of tumor stroma on tumor cells,and inhibits the occurrence,growth,and metastasis of lung cancer.Decreased expression of PTEN gene leads to the development of drug resistance in lung cancer treatment and reflects the prognosis of patients.However,due to the existence of epigenetic and post-translational regulation,PTEN protein deletion is significantly higher than the incidence of PTEN gene mutation.Therefore,compared with PTEN gene targeting therapy drugs,improving the expression of PTEN protein in lung cancer may be a more promising approach to PTEN gene therapy for lung cancer and inhibiting drug resistance.

关 键 词：肺癌 PTEN基因 耐药 治疗 

分 类 号：R734[医药卫生—肿瘤]